Active — Not RecruitingNot Applicable

Reducing Risk of Dementia Through Deprescribing

United States344 participantsStarted 2020-07-20

Plain-language summary

A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. ICD-9/10 codes, or
✕. Current use of a medication for Alzheimer's Disease or a Related Dementia, or
✕. A pattern of responses to the Functional Activities Questionnaire (FAQ) that indicate dementia (i.e., ≥ 3 FAQ items are scored at "requires assistance," or if ≥ 1 FAQ item is scored at "dependent").

What they're measuring

Change in Cognitive Composite Score

Timeframe: Baseline, 6, 12, 18, and 24 months

Change in Patient Reported Outcome Measurement Information System (PROMIS)

Timeframe: Baseline, 6, 12, 18, and 24 months

Change in Health Utilities Index (HUI)

Timeframe: Baseline, 6, 12, 18, and 24 months

Trial details

NCT IDNCT04270474

SponsorIndiana University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-30

View on ClinicalTrials.gov More Dementia trials